<h3>カブリビはこれまでの後天性TTP治療とどう違うのでしょうか？</h3>

公開日　2023年11月22日
<h3 style="text-align:center;">薬剤（カブリビ）</h3>
&nbsp; &nbsp;微小血栓形成の直接阻害 &nbsp;&nbsp; &nbsp;&nbsp; &nbsp; &nbsp; 作用機序 &nbsp; &nbsp;

監修：松本 雅則 先生（奈良県立医科大学 血液内科学講座 教授・輸血部 部長）

カブリビは後天性TTPにおける微小血栓形成を直接阻害する点で、これまでの治療法と全く異なります。 
 従来の治療では、ADAMTS13の補充やADAMTS13自己抗体の除去を目的とする血漿交換や、自己抗体産生抑制を目的とする免疫抑制薬を用います。カブリビはADAMTS13に・・・

続きの回答を見るには会員登録が必要です。 
 是非ログインまたは会員登録ください。

black

Q. カブリビと従来の後天性TTP治療の違い

SPECIALTY-CARE

RARE-BLOOD-DISORDERS

CABLIVI

ACQUIRED-THROMBOTIC-THROMBOCYTOPENIA-PURPURA-ATTP

HEMATOLOGY

To read the full content, activate your Sanofi Campus account. Please confirm your email address in the email you received.

If you didn't receive our first email at {email} to confirm your account you can request a new one below. If you don't see it, you may need to check your spam folder.

This information will only be used to validate your account and will not be distributed.

title

Before starting exploring, we can suggest you specific and relevant content

Title

Quick Summary

This website is for healthcare professionals only.

Welcome to BP Sanofi Campus

Create new password

パーソナライズ体験をご利用いただくため、プロファイルの設定をお願いいたします。

プロファイルが未完成です

The ADCT gives a measure of how controlled the eczema is. Answer these 6 simple questions with your patient to find the ADCT score. It will indicate proper course of action.

Atopic dermatitis, a type of eczema, may be affecting your Patient's life in more ways than you know.

Take the Atopic Dermatitis Control Test (ADCT)

Enjoy more exclusive content{newline}by <a>registering today</a>

Already have an account? <a>Sign in here</a>

Best practices on optimising patient care

Get a customised view of the topics that you're interested in, along with the ability to save content to watch or read at a later date.

Unlimited access to premier content, white papers, case studies, research papers, webinars, training, and up-to-date scientific medical resources.

Personalised content based on your areas of interest

Connect and stay up-to-date with peers in your area of speciality and topics of interest through free events and leadership forums.

Please sign in to continue and read the full article

Please sign up to continue reading the full article.

We respect your privacy and will not share your information with any 3rd parties.

Topical guides written specifically for patients

Unlimited access to the latest patient guide guides and resources. Share content with your patients with easy-to-use online tools.

Please complete your profile to read the content.

Your profile is not validated yet. Please verify your inbox.

Restricted Access

We can't find the page you're looking for

You are going to a website that is not operated by Sanofi. Sanofi has no control over the content or availability of linked sites or resources, and accepts no liability or responsibility for them or for any loss or damage that may arise from your use of them. Please ensure that you read the legal and privacy policy sections of any third-party site to which you link.

You are about to leave Sanofi Campus website.

You are now leaving this site to visit a partner website.

Thank you for visiting COPD Sanofi Campus.

Welcome to COPD Sanofi Campus.

Welcome to COPD Sanofi Campus

Welcome to CSU Sanofi Campus

Please refresh the page to access the content

Sorry, something went wrong

検索結果が見つかりませんでした。キーワードを変えてもう一度お試しください。

検索結果が見つかりませんでした。

Campusから離れ、外部サイトへ移動します

You are about to leave Campus.sanofi/uk.

プライバシー通知の更新 | 当社は、医療従事者向けのプライバシー通知を更新しました。本更新により、当社とのコラボレーションにおける体験の向上を図るとともに、高いプライバシー基準を維持し、最終的に当社への信頼を一層高めることを目的としています。主な変更点として、サノフィが個人データを処理する目的およびその方法を、より分かりやすく明確化しています。

Thank you for registering. Before we get started, we need to confirm your email address to ensure that we have the correct information.

Please follow these steps to complete your registration:

Would you like to receive future text messages about Beyfortus updates?

Sanofi is here to help support your patients, their families, and caregivers. For more information regarding Beyfortus® (nirsevimab-alip) Injection, call <a.callPhoneNumberBeyfortus>1-855-BEYFORTUS (1-855-239-3678)</a.callPhoneNumberBeyfortus> or sign up below to receive the latest updates via email. All fields are required.

Would you like to learn more about Beyfortus® (nirsevimab-alip) 50 mg and 100 mg injection? Leave us your contact details, and a Sanofi representative will be in touch. All fields are required.

Would you also like to receive future messages and updates about Beyfortus?

Do you want to participate in the Beyfortus Reservation Program?

What information are you interested in learning more about? (Optional)

Are you enrolled in CENRIFKI REMS?

Request a visit from your local ALPROLIX representative to learn more. Call <a.callPhoneNumberAltuviiio>1-800-745-4447</a.callPhoneNumberAltuviiio>, Option 5, or complete the form below. The information you provide will be maintained in accordance with our <a.usPrivacyPolicy>Privacy Policy</a.usPrivacyPolicy>. All fields are required.

Request a visit from your local ALTUVIIIO representative to learn more. Call <a.callPhoneNumberAltuviiio>1-800-745-4447</a.callPhoneNumberAltuviiio>, Option 5, or complete the form below. The information you provide will be maintained in accordance with our <a.usPrivacyPolicy>Privacy Policy</a.usPrivacyPolicy>. All fields are required.

Request a visit from your local QFITLIA representative to learn more. Call <a.callPhoneNumberAltuviiio>1-800-745-4447</a.callPhoneNumberAltuviiio>, Option 5, or complete the form below. The information you provide will be maintained in accordance with our <a.usPrivacyPolicy>Privacy Policy</a.usPrivacyPolicy>. All fields are required.

Sign up to schedule an office visit with your ALPROLIX® Representative or receive updates about ALPROLIX. Please complete the form below. The information you provide will be maintained in accordance with our <a.usPrivacyPolicy>Privacy Policy</a.usPrivacyPolicy>. All fields are required.

Sign up to schedule an office visit with your local Sanofi representative and/or to receive updates about Qfitlia. Please complete the form below. The information you provide will be maintained in accordance with our <a.usPrivacyPolicy>Privacy Policy</a.usPrivacyPolicy>. All fields are required (unless otherwise specified).

All fields are required. (unless otherwise specified)

本サイトは医療従事者の皆様向けの情報サイトです。サノフィの医薬品情報や教育資材などをご覧いただけます。
下記のボタンをクリックして進むことで、医療従事者であることを確認したものとみなされます。本サイトには販促情報を含む場合があり、一部のコンテンツは医療従事者のみ閲覧可能です。

サノフィ キャンパスへようこそ

Welcome to ITP Sanofi Campus

This content is only available to registered users. Please sign in or register to view this content.

Please Sign In

Email verification

You're seeing a preview of the portal. Clear your cookies (by closing your browser window for example) to go back to public mode.

We've updated our privacy notice to better protect your data and enhance your experience. Please take a moment to review the changes by <privacyNewTab>clicking here</privacyNewTab>. Your privacy matters for us. Please click on continue to confirm you have read the new privacy notice.

Privacy Notice Update

Communication consent

My consents

Password

Confirm password

{resultsCount, plural, one {result} other {results}}

Please log in to access to the results

You need to sign-in to your account in order to access medical content.

Please Log In

To access the results, please register in under 1 minute

You are now leaving the Sanofi content section of our site and entering the external medical bibliographic search content section.

You are entering to the External Scientific Content Site

You are now leaving the external medical bibliographic search section of our site and entering the Sanofi content section.

Q. カブリビと従来の後天性TTP治療の違い

カブリビはこれまでの後天性TTP治療とどう違うのでしょうか？

薬剤（カブリビ）

続きの回答を見るには会員登録が必要です。 是非ログインまたは会員登録ください。

続きの回答を見るには会員登録が必要です。
是非ログインまたは会員登録ください。